05.01.26 -- Reprogramming T Cells And Reducing Manufacturing Costs With Michael McCullar

High screen fail rates delay trials, raise costs, and limit access. Learn the root causes, recruitment impact, and why underrepresented groups are hit hardest — and how to reduce failures early.

Focus AI validation on decision impact rather than just algorithms. Aligning assurance with intended use and human oversight ensures safety while enabling faster, more compliant adoption.

Policy changes are reshaping PBM oversight, advancing price transparency, and influencing global drug development — affecting affordability, patient access, and the future of pharma innovation.

Embrace a broader approach to diversity in clinical trials by addressing social determinants of health and designing inclusive studies that ensure equitable representation and access to all patients.

Meet a clinical research participant who has spent her life navigating the challenges of cystic fibrosis, leading her to become an advocate, amplifying the voices of others facing similar struggles.

Cell therapy’s future hinges not just on scientific progress but on scalable manufacturing. Explore why reliability and productivity now shape viability and how modernizing operations can support growth.